New nasal spray for allergies passes first safety check
NCT ID NCT07345442
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new corticosteroid nasal spray called PA9159 in 36 healthy Chinese adults. Participants received either a single dose or seven daily doses of the spray, or a placebo. The goal was to find the maximum safe dose and see how the drug moves through the body. This is a first step toward possibly treating allergic rhinitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PA9159 (a novel corticosteroid) nasal spray
What this could lead to
If successful, this could lead to a new treatment option for allergic rhinitis symptoms.
What could go wrong
This is a very early Phase 1 safety study with only 36 healthy people, not patients. It does not test effectiveness, and the drug may not work or may have side effects in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China